CDK4/6 Inhibition Enhances CAR-T Cell Therapy in Solid Tumors - PubMed
5 hours ago
- #Solid Tumors
- #CAR-T Therapy
- #CDK4/6 Inhibitors
- CDK4/6 inhibitors enhance CAR-T cell cytotoxicity and metabolic fitness but reduce expansion in vitro.
- Combination therapy outperforms monotherapies in RB-proficient cancer models but not in RB-deficient ones.
- In solid tumors, the combination consistently shows higher efficacy than single agents.
- CDK4/6 inhibition reduces tumor-infiltrating T-regulatory cells and improves CAR-T cell persistence and function.
- Trilaciclib may be an effective adjuvant to CAR-T therapy in solid cancers.